Alina R.
- Country
- Portugal
- Department
- Oncology
Research Overview
- Phase 3 Randomized Double-Blind Study of Talazoparib and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Phase 3 Randomized, Double-Blind Study of Bemarituzumab with mFOLFOX6 in FGFR2b-Overexpressing Advanced Gastric or Gastroesophageal Junction Cancer
- Phase 1b/3 Evaluation of Bemarituzumab, Chemotherapy, and Nivolumab in FGFR2b-Overexpressing Advanced Gastric and Gastroesophageal Junction Cancer
Data & Insights
Has run more than one trial at 47 of 218 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating advanced forms of prostate cancer, with particular expertise in managing metastatic castration-resistant prostate cancer (mCRPC).
- Hormonal Therapy Resistance
- Metastatic Disease Management
- Advanced Stage Treatment
Their work encompasses innovative therapeutic approaches for patients with progressive disease states.
Gastrointestinal Oncology
The investigator has developed expertise in treating advanced gastric cancer and gastroesophageal junction tumors, with a focus on molecular-targeted therapies.
- FGFR2b Expression Analysis
- Upper GI Tract Malignancies
- First-line Treatment Strategies
Their work includes evaluation of targeted therapies in combination with standard chemotherapy protocols.
Therapeutic Innovation
The investigator explores novel treatment combinations including targeted therapies and their integration with established treatment modalities.
- Combination Therapy Approaches
- Molecular Targeting
- Treatment Optimization
Their expertise extends to evaluating therapeutic efficacy in specific patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.